Ocular Therapeutix (OCUL) Surges on Regeneron (REGN) Collaboration

October 13, 2016 8:38 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Ocular Therapeutix (NASDAQ: OCUL) is surging 29% in pre-open trade after the company entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN). Ocular and Regeneron will collaborate on thedevelopment of a sustained release formulation of the vascular endothelial growth factor (VEGF) trap aflibercept for the treatment of wet age-related macular degeneration (wet AMD) and other serious retinal diseases.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Momentum Movers, Trader Talk

Related Entities

Pre Market Movers

Add Your Comment